Filing Flows › Comparisons › PRCT vs ANGO
Procept BioRobotics vs Angiodynamics: PRCT and ANGO compared
Procept BioRobotics is the larger company: $98.3M of revenue in its latest quarter (Q3 2026) against $80.9M for Angiodynamics (Q1 FY27). Procept BioRobotics is growing faster (+18% against +7% a year earlier). Angiodynamics is more profitable, with an operating margin of -9.0% against -27.9%.
Where the money goes: PRCT and ANGO
Procept BioRobotics (PRCT) · Q3 2026
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
Angiodynamics (ANGO) · Q1 FY27
Angiodynamics, Q1 FY27: revenue $80.9M (+7% year over year), operating margin -9.0%, net loss $7.1M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
| Procept BioRobotics (PRCT) | Angiodynamics (ANGO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY27 |
| Revenue | $98.3M | $80.9M |
| Revenue growth, Y/Y | +18% | +7% |
| Operating margin | -27.9% | -9.0% |
| Net earnings | −$26.5M | −$7.1M |
| Net margin | -27.0% | -8.8% |
| Operating cash flow | −$9.0M | −$15.3M |
| Market value | $1.1B | $484M |
| Analysts’ mean target | $22.58 | $19.75 |
Where the revenue comes from
Angiodynamics
- Med Device: $41.0M (51%)
- Med Tech: $39.9M (49%)
Questions
Which is bigger, Procept BioRobotics or Angiodynamics?
Procept BioRobotics is the larger company: $98.3M of revenue in its latest quarter (Q3 2026) against $80.9M for Angiodynamics (Q1 FY27).
Is Procept BioRobotics or Angiodynamics growing faster?
Procept BioRobotics is growing faster (+18% against +7% a year earlier).
Which is more profitable, Procept BioRobotics or Angiodynamics?
Angiodynamics is more profitable, with an operating margin of -9.0% against -27.9%.
More: Procept BioRobotics earnings · how Procept BioRobotics makes money · Angiodynamics earnings · how Angiodynamics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Oct 8, 2026). Fiscal quarters can end on different dates. Not investment advice.